Cargando…

Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04

BACKGROUND: There has been limited evaluation of health‐related quality of life (HRQOL) in rectal cancer patients receiving neoadjuvant chemoradiotherapy. HRQOL outcomes in the National Surgical Adjuvant Breast and Bowel Project R‐04 trial are examined in this article. METHODS: Between 2004 and 2010...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganz, Patricia A., Hays, Ron D., Spritzer, Karen L., Rogatko, André, Ko, Clifford Y., Colangelo, Linda H., Arora, Amit, Hopkins, Judith O., Evans, Terry L., Yothers, Greg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540677/ https://www.ncbi.nlm.nih.gov/pubmed/35749631 http://dx.doi.org/10.1002/cncr.34341

Ejemplares similares

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35
por: Henry, N. Lynn, et al.
Publicado: (2021)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial
por: Calsavara, Vinicius F., et al.
Publicado: (2023)

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
por: Kim, S Rim, et al.
Publicado: (2018)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
por: Pogue-Geile, Katherine L, et al.
Publicado: (2020)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
por: George, Thomas J., et al.
Publicado: (2015)

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data
por: Calsavara, Vinicius F., et al.
Publicado: (2022)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index
por: Gresham, Gillian, et al.
Publicado: (2020)

Restaging rectal cancer following neoadjuvant chemoradiotherapy
por: Cuicchi, Dajana, et al.
Publicado: (2023)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III Trial
por: Diefenhardt, Markus, et al.
Publicado: (2022)

Talking numbers: how women and providers use risk scores during and after risk counseling – a qualitative investigation from the NRG Oncology/NSABP DMP-1 study
por: Blakeslee, Sarah B, et al.
Publicado: (2023)

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer()()
por: Smithson, Mary, et al.
Publicado: (2022)

Primary chemotherapy for operable breast cancer: the NSABP experience
por: Bear, HD
Publicado: (2005)

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Li, Yi, et al.
Publicado: (2016)

Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Kawai, Kazushige, et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Travaini, Laura L, et al.
Publicado: (2016)

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
por: Molinari, Chiara, et al.
Publicado: (2011)

Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients
por: Tokuhara, Katsuji, et al.
Publicado: (2016)

Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer
por: Mihmanlı, Mehmet, et al.
Publicado: (2016)

Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
por: Yamashita, Kimihiro, et al.
Publicado: (2018)

Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients
por: Mei, Shi-Wen, et al.
Publicado: (2020)

Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer
por: Filitto, Giuseppe, et al.
Publicado: (2022)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Hanyang, et al.
Publicado: (2022)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
por: Diniz, Márcio A., et al.
Publicado: (2021)

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Toomey, Sinead, et al.
Publicado: (2020)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1
por: Amir, Eitan, et al.
Publicado: (2012)

MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer
por: Meng, Yankai, et al.
Publicado: (2017)

Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Yoo, Ri Na, et al.
Publicado: (2019)

Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer
por: Chen, Jia-Nan, et al.
Publicado: (2020)

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy
por: Guo, Su-ping, et al.
Publicado: (2021)

Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
por: Zhang, Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j4ehu9pin2e7560o5l6f6idoim